978 related articles for article (PubMed ID: 22437502)
1. Crystal structure of the µ-opioid receptor bound to a morphinan antagonist.
Manglik A; Kruse AC; Kobilka TS; Thian FS; Mathiesen JM; Sunahara RK; Pardo L; Weis WI; Kobilka BK; Granier S
Nature; 2012 Mar; 485(7398):321-6. PubMed ID: 22437502
[TBL] [Abstract][Full Text] [Related]
2. Structural insights into µ-opioid receptor activation.
Huang W; Manglik A; Venkatakrishnan AJ; Laeremans T; Feinberg EN; Sanborn AL; Kato HE; Livingston KE; Thorsen TS; Kling RC; Granier S; Gmeiner P; Husbands SM; Traynor JR; Weis WI; Steyaert J; Dror RO; Kobilka BK
Nature; 2015 Aug; 524(7565):315-21. PubMed ID: 26245379
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors.
Neumeyer JL; Zhang A; Xiong W; Gu XH; Hilbert JE; Knapp BI; Negus SS; Mello NK; Bidlack JM
J Med Chem; 2003 Nov; 46(24):5162-70. PubMed ID: 14613319
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
Mathews JL; Peng X; Xiong W; Zhang A; Negus SS; Neumeyer JL; Bidlack JM
J Pharmacol Exp Ther; 2005 Nov; 315(2):821-7. PubMed ID: 16076937
[TBL] [Abstract][Full Text] [Related]
5. Structure of the µ-opioid receptor-G
Koehl A; Hu H; Maeda S; Zhang Y; Qu Q; Paggi JM; Latorraca NR; Hilger D; Dawson R; Matile H; Schertler GFX; Granier S; Weis WI; Dror RO; Manglik A; Skiniotis G; Kobilka BK
Nature; 2018 Jun; 558(7711):547-552. PubMed ID: 29899455
[TBL] [Abstract][Full Text] [Related]
6. Propagation of conformational changes during μ-opioid receptor activation.
Sounier R; Mas C; Steyaert J; Laeremans T; Manglik A; Huang W; Kobilka BK; Déméné H; Granier S
Nature; 2015 Aug; 524(7565):375-8. PubMed ID: 26245377
[TBL] [Abstract][Full Text] [Related]
7. Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives as μ/κ Opioid Receptor Dual Selective Ligands.
Zheng Y; Obeng S; Wang H; Jali AM; Peddibhotla B; Williams DA; Zou C; Stevens DL; Dewey WL; Akbarali HI; Selley DE; Zhang Y
J Med Chem; 2019 Jan; 62(2):561-574. PubMed ID: 30608693
[TBL] [Abstract][Full Text] [Related]
8. Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan analogues as opioid receptor ligands.
Yuan Y; Zaidi SA; Stevens DL; Scoggins KL; Mosier PD; Kellogg GE; Dewey WL; Selley DE; Zhang Y
Bioorg Med Chem; 2015 Apr; 23(8):1701-15. PubMed ID: 25783191
[TBL] [Abstract][Full Text] [Related]
9. Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
Ananthan S; Khare NK; Saini SK; Seitz LE; Bartlett JL; Davis P; Dersch CM; Porreca F; Rothman RB; Bilsky EJ
J Med Chem; 2004 Mar; 47(6):1400-12. PubMed ID: 14998329
[TBL] [Abstract][Full Text] [Related]
10. Exploring pharmacological activities and signaling of morphinans substituted in position 6 as potent agonists interacting with the μ opioid receptor.
Ben Haddou T; Malfacini D; Calo G; Aceto MD; Harris LS; Traynor JR; Coop A; Schmidhammer H; Spetea M
Mol Pain; 2014 Jul; 10():48. PubMed ID: 25059282
[TBL] [Abstract][Full Text] [Related]
11. Morphinan Evolution: The Impact of Advances in Biochemistry and Molecular Biology.
Kajino K; Tokuda A; Saitoh T
J Biochem; 2024 Mar; 175(4):337-355. PubMed ID: 38382631
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist.
Neilan CL; Husbands SM; Breeden S; Ko MC; Aceto MD; Lewis JW; Woods JH; Traynor JR
Eur J Pharmacol; 2004 Sep; 499(1-2):107-16. PubMed ID: 15363957
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine dependence.
Neumeyer JL; Bidlack JM; Zong R; Bakthavachalam V; Gao P; Cohen DJ; Negus SS; Mello NK
J Med Chem; 2000 Jan; 43(1):114-22. PubMed ID: 10633042
[TBL] [Abstract][Full Text] [Related]
14. Structure-based design of bitopic ligands for the µ-opioid receptor.
Faouzi A; Wang H; Zaidi SA; DiBerto JF; Che T; Qu Q; Robertson MJ; Madasu MK; El Daibani A; Varga BR; Zhang T; Ruiz C; Liu S; Xu J; Appourchaux K; Slocum ST; Eans SO; Cameron MD; Al-Hasani R; Pan YX; Roth BL; McLaughlin JP; Skiniotis G; Katritch V; Kobilka BK; Majumdar S
Nature; 2023 Jan; 613(7945):767-774. PubMed ID: 36450356
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and binding affinity of novel mono- and bivalent morphinan ligands for κ, μ, and δ opioid receptors.
Zhang B; Zhang T; Sromek AW; Scrimale T; Bidlack JM; Neumeyer JL
Bioorg Med Chem; 2011 May; 19(9):2808-16. PubMed ID: 21482470
[TBL] [Abstract][Full Text] [Related]
17. Structure selectivity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives toward the development of the mu opioid receptor antagonists.
Yuan Y; Elbegdorj O; Chen J; Akubathini SK; Beletskaya IO; Selley DE; Zhang Y
Bioorg Med Chem Lett; 2011 Sep; 21(18):5625-9. PubMed ID: 21788135
[TBL] [Abstract][Full Text] [Related]
18. Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constraints.
Pogozheva ID; Lomize AL; Mosberg HI
Biophys J; 1998 Aug; 75(2):612-34. PubMed ID: 9675164
[TBL] [Abstract][Full Text] [Related]
19. Ligand based conformational space studies of the μ-opioid receptor.
Sena DM; Cong X; Giorgetti A
Biochim Biophys Acta Gen Subj; 2021 Mar; 1865(3):129838. PubMed ID: 33373630
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of unique morphinan-type molecules: Their application to the search for the unexplored binding domain between opioid receptors and morphinan ligands.
Maeda K; Sugai T; Tokuda A; Kajino K; Saitoh T; Nagase H; Kutsumura N
Bioorg Med Chem Lett; 2024 Feb; 99():129611. PubMed ID: 38228254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
